Invited Speaker Australian and New Zealand Stroke Organisation Conference 2025

Temporal dynamics of the no-reflow phenomenon on serial perfusion MRI post-thrombectomy (123262)

Samantha Rivet 1 , Leonid Churilov 2 , Vincent Thijs 3 , Mark W Parsons 4 , Stephen M David 1 , Peter J Mitchell 5 , Bruce CV Campbell 1 , Felix Ng 1
  1. Medicine and Neurology, Royal Melbourne Hospital, Parkville, VIC, Australia
  2. Melbourne Medical School, University of Melbourne, Melbourne, VIC, Australia
  3. Neurology, Austin Hospital, Heidelberg, VIC, Australia
  4. University of New South Wales, Sydney, NSW, Australia
  5. Radiology, Royal Melbourne Hospital, Parkville, VIC, Australia

Background/Aim: The no-reflow phenomenon, observed in 30% of ischemic stroke patients despite technically successful thrombectomy, is associated with poor outcomes. Its temporal evolution in humans remains uncharacterised. We examined the temporal dynamics of no-reflow through serial MRI perfusion imaging within 48-hours post-thrombectomy.

Methods: In a multicentre prospective study, 67 ischemic stroke patients with acute anterior large vessel occlusion underwent serial post-thrombectomy MRI within 3-hours post-procedure (timepoint 1, TP1) and at 24–48 hours (timepoint 2, TP2). No-reflow was defined as visually-detectable hypoperfusion within the infarct with >15% median relative cerebral blood volume (rCBV) or flow (rCBF) reduction compared to mirror homolog, after complete/near-complete angiographic reperfusion (eTICI 2c-3). No-reflow was assessed globally (entire DWI-positive lesion at TP2) and within two subregions (early infarction: DWI-positive at TP1 and TP2; infarct growth: DWI-positive at TP2 only).

Results: 29 patients achieving eTICI 2c-3 were included. At TP1, 4 patients (14%) exhibited global no-reflow and 2 patients showed no-reflow within a subregion (21% total). At TP2, 7 patients (24%) demonstrated global no-reflow, with no case of isolated regional no-reflow observed. By TP2, 2 patients showed resolution of no-reflow, 1 progressed from regional to global no-reflow, and 3 developed late-onset no-reflow. Global no-reflow at TP2 was associated with worse outcomes (mRS 0-1: OR 0.14, 95%CI 0.02–0.84, p=0.03) but not at TP1 (OR 0.16, 95%CI 0.02–1.33, p=0.09).

Conclusion: No-reflow manifests early after successful thrombectomy and frequently persists, contributing to worse patient outcomes. Cases of resolution and progression suggest a dynamic and reversible pathology potentially amenable to timely treatment.